https://doi.org/10.55788/a3e97b53
“IVUS provides detailed information on vessel dimensions and plaque characteristics; however, there has been limited clinical data on the benefit of IVUS in the endovascular treatment of femoropopliteal artery disease using drug-coated balloons (DCBs),” Prof. Young-Guk Ko (Severance Cardiovascular Hospital; Yonsei University, South Korea) explained the study background [1].
The investigator-initiated, randomised-controlled IVUS-DCB trial (NCT03517904) compared IVUS-guided with angiography-guided angioplasty with DCB for patients with femoropopliteal artery disease. The main study outcome was defined as primary patency (i.e. absence of clinically driven target lesion revascularisation [CD-TLR] or binary stenosis on imaging) at 12 months. The 237 participants were predominantly men (85%) and had a mean age of around 70 years. The average lesion length was between 204.9 mm and 214.5 mm with about two-third being complex lesions of TransAtlantic Inter-Society Consensus (TASC)2 type C/D.
The immediate procedural outcomes included technical success in 76.5% on IVUS and 61% on angiography (P=0.02) and procedural success in 73.9% compared with 60.2% (P=0.03), respectively. “In the IVUS group, the post-procedural ankle-brachial index was significantly higher, reflecting better haemodynamic results after the treatment,” stated Prof. Ko.
In the intention-to-treat analysis at 12 months, the primary outcome results showed superiority for IVUS guidance with patency rates of 83.8% compared with 70.1% in the angiography group (HR 0.46; 95% CI 0.25–0.85; P=0.01). The per-protocol analysis showed similar results. “When we broke down the target lesions according to their complexity into the TASC2 A/B subgroup and the TASC2 C/D subgroup, the clinical benefit in terms of primary patency was evident only in complex lesions,” Prof. Ko added.
The percentage of participants free from CD-TLR, a secondary endpoint, was 92.4% compared with 83.0% (HR 0.41; 95% CI 0.19–0.90; P=0.03). Among the significant predictors of re-stenosis identified by a univariate model were lesion length ≥200 mm (P=0.002) and post-procedural minimal lumen diameter (P<0.001).
- Ko YG. Comparison of Intravascular Ultrasound-guided versus Angiography-guided Angioplasty for the Outcomes of Drug-coated Balloon in the Treatment of Femoropopliteal Artery Disease. LB5, Session 412, ACC 2024 Scientific Session, 6–8 April, Atlanta, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
Interatrial shunt for HF: neutral primary endpoint but potential benefit in HFrEF »
« Letter from the Editor Next Article
Interatrial shunt for HF: neutral primary endpoint but potential benefit in HFrEF »
Table of Contents: ACC 2024
Featured articles
Matters of the heart: late-breaking news from the American College of Cardiology
Heart Failure and Cardiomyopathy
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
IMPROVE-HCM: Promising results for ninerafaxstat in non-obstructive HCM
Acute Coronary Syndrome and Acute Myocardial Infarction
ACS: Necessary DAPT after PCI may be shorter than currently advised
AEGIS-II: ApoA-1 did not reduce MACE in patients with myocardial infarction but may provide benefit in patients with high LDL levels
REDUCE-AMI: Re-evaluating the role of routine beta-blockade in patients with acute myocardial infarction
Interventional Cardiology in 2024
Self-expanding versus balloon-expendable TAVR in patients with small aortic annuli
Safety of TAVI non-inferior to SAVR for patients with lower surgical risk
Interatrial shunt for HF: neutral primary endpoint but potential benefit in HFrEF
Peripheral artery disease: procedure-guidance by IVUS superior to angiography
IVUS-guided PCI beats angiography in patients with acute coronary syndrome
Addressing frailty in patients undergoing TAVR
Novel Developments in Risk Factor Management
Preventive PCI of vulnerable intracoronary plaque leads to favourable outcomes
KARDIA-2: Add-on zilebesiran effectively lowers blood pressure
BRIDGE-TIMI 73a: Olezarsen halves triglyceride levels
Plozasiran: A novel approach to severe hypertriglyceridaemia
High-risk and very high-risk patients meet LDL-cholesterol targets with lerodalcibep
No cardioprotective effect of ACE inhibitors in patients with cancer
Best of Posters
SGLT2 inhibition in heart failure more advantageous for women than men
Anxiety and depression: Lifestyle influential in MACE prevention
Meet the Trialists
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com